Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

The company said the trial will continue unchanged as per the recommendation of a data monitoring committee. The trial was testing Bristol-Myers' drugs Opdivo and Yervoy, against Opdivo alone, in patients with advanced melanoma. The combination failed to show a statistically significant benefit in patients whose tumors had 1% or lower levels of the PD-L1 protein being targeted, the company said. The American Cancer Society estimates that about 96,480 melanoma cases will be diagnosed in the United States this year. Bristol-Myers shares were trading at $55.99 before the bell.
Bristol-Myers misses main goal of late-stage skin cancer trial.

Environmental groups strongly oppose the practice of hydraulic fracturing, or fracking, which involves extracting gas from rocks by breaking them up with water and chemicals at high pressure. But the government, keen to cut Britain's reliance on imports as North Sea gas supplies dry up, has tightened regulations and has given Cuadrilla permission to frack two wells at its Preston New Road site in Lancashire. Cuadrilla, 47.4 percent owned by Australia's AJ Lucas and 45.2 percent owned by a fund managed by Riverstone, said it would spend at least three months fracking two horizontal wells to test flow rates to determine whether full-scale gas extraction would be viable. The British Geological Survey estimates shale gas resources in northern England alone could amount to 1,300 trillion cubic feet (tcf) of gas, 10 percent of which could meet the Britain's demand for almost 40 years. "Shale gas has the potential to be a new domestic energy source, enhancing our energy security and delivering economic benefits, including the creation of well-paid, quality jobs," the Department for Business, Energy and Industrial Strategy said. "We have been clear that any shale developments must be safe and environmentally sound," the department added in a statement. Attempts to extract the gas have come under fire from local communities and campaigners concerned about the potential effect on the environment and ground water. They say extracting more fossil fuel is at odds with Britain's commitment to reduce greenhouse gas emissions. "It is morally bankrupt to be heralding the start of a whole new fossil fuel industry," Craig Bennett, chief executive of environmental group Friends of the Earth said in a statement. "You can deal with climate change or you can have fracking you can't do both," he said. The government asked its climate advisers on Monday to examine whether Britain should toughen its climate targets and set a date to move to a net zero emissions goal. Britain has an existing target to cut its greenhouse gas emissions by 80 percent compared with 1990 levels by 2050.
Britain's Cuadrilla starts fracking for gas after seven-year pause.

"SInce the test drug is in the very early stages of development, this criterion is technically not applicable. However, the present treatment regimen of an interferon and ribavirin costs thousands of dollars monthly for 6-12 months and it is likely that any newer antivirals will be additive and not replacements. A comment on the potential for significant additional costs would have been desirable. The story got a little carried away here. It said participants treated with the experimental drug had a ""dramatic"" reduction in viral load. While this may be true, it would have been helpful to point out, as the HealthDay story did, that the study lasted only a few days. We don't know whether this benefit can be maintainedover a longer period of time, especially considering that thehepatitis C virus has proven to be quite capable of developing resistance to antivirals over time. The story says study participants who took the drug exhibited ""few side effects."" But what were those side effects and how serious were they? The story doesn't say. While the implication here is that the drug seems to be safe a conclusion that we can't really draw based on a small, early phase test the story does include acautionary quote from an expert about the need for additional testing to demonstrate safety. It also noted that patients taking this drug might still need to be treated with interferon, which many individuals can't tolerate because of side effects. A close one, but we'll call it satisfactory. This story includes appropriate caveats about the early nature of this research and includes a restraining quote from an expert who warns that the drug might not make it out of phase II tests. Unlike the competing HealthDay piece, this story resisted getting too worked up about the other experimental drugs for hepatitis-C that are closer to potential FDA approval. This story does not exaggerate the prevalence or severity of hepatitis C. According to disclosure statements from a 2008 CME program,Dr. Bruce Bacon, an expert source for this story, received research funding from Bristol Myers Squibb, which is developing the experimental drug being discussed. He also is a consultant to drug companies developing competing drugs for hepatitis C.To avoid the appearance of a conflict of interest it is desirable to identifyrelationships such as these clearly. This story fails to do so. The story compares the new drug with intravenously administered peg-interferon and ribavirin the currentstandard of carefor hepatitis C. The story called the research on BMS-790052 ""preliminary"" and made it clear thatthe drugwas not close to approval. It also was more cautious than the competing HealthDay piece in its description of two other antiviral drugs that are nearing FDA approval. The story notes that there are many other drugs being developed to treat hepatitis C. It explained that a potentially novel advantage of the new compound is that it seems to be effective against all genotypes. We can't be sure whether this story relied on a news release."
Experimental Drug May Treat Hepatitis C